Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists
Survey-based opinions can effectively capture treatment selection preferences for mUC and could inform future clinical trial design. Additional data, including the impact of residual toxicity from 1L EVP, are needed to better understand real-world treatment sequencing patterns.
Authors
- Ali Raza Khaki (ORCID: https://orcid.org/0000-0002-4655-4426)
- Karine Tawagi (ORCID: https://orcid.org/0009-0001-3416-3786)
- Peter H. O’Donnell (ORCID: https://orcid.org/0000-0003-2650-0049)
- Petros D. Grivas (ORCID: https://orcid.org/0000-0003-3965-3394)
- Priyanka V. Chablani
- Vadim S. Koshkin (ORCID: https://orcid.org/0000-0003-2277-8668)
- Elizabeth R. Plimack (ORCID: https://orcid.org/0000-0002-7618-0744)
- Jean Hoffman‐Censits (ORCID: https://orcid.org/0000-0002-6970-6509)
- Jonathan E. Rosenberg (ORCID: https://orcid.org/0000-0003-2637-4249)
- Matt D. Galsky
- Shilpa Gupta
Institutions
- Fox Chase Cancer Center (US)
- Cleveland Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Johns Hopkins University (US)
- University of Pittsburgh (US)
- University of California, San Francisco (US)
- University of Washington (US)
- University of Illinois Chicago (US)
- Fred Hutch Cancer Center (US)
- Tisch Hospital (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Stanford University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Genitourinary Cancer
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1016/j.clgc.2025.102487
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00